SIU 2017: Dynamic Real-Time Microscopy of Bladder Neoplasms Using Confocal Laser Endomicroscopy

Lisbon, Portugal ( In this study, the authors assess the role of random bladder biopsies. While recent guidelines have already indicated the role of random bladder biopsies (typically in setting of positive cytology but negative cystoscopy, or in consideration of partial cystectomy), the authors complete a single institution assessment of predictors of positive bladder biopsies. 

SIU 2017: Relation of ALDH1a and CD44 with Clinicopathological Factors in Transitional and Squamous Cell Carcinomas of Urinary Bladder

Lisbon, Portugal ( Cancer stem cells, usually representing a small 1-2% of the tumor volume, may be resistant to traditional therapy and may be a source of treatment resistant and disease progression. There are various CSC markers that are being evaluated for association with CSC presence and subsequently disease aggressiveness and treatment response. ALDH1a and CD44 are two such markers of CSC.

SIU 2017: Overexpression of Epidermal Growth Factor Receptor Predicts Bladder Cancer Local Aggressiveness

Lisbon, Portugal ( this abstract, the authors examine the prognostive value of EGFR (epidermal growth factor receptor). EGF is important for cell proliferation, differentiation and invasion, and may contribute to tumorigenesis. It is often reported on IHC analysis in pathology reports for patients with bladder resections. The authors hypothesize that higher EGFR levels on IHC is associated with more aggressive bladder cancer.

SIU 2017: Second Look Transurethral Resection of Bladder Tumor: Is It Necessary in All T1 and/or High Grade Tumors?

Lisbon, Portugal ( Repeat TURBT after an initial diagnosis of NMIBC, specifically high-grade T1 disease, is recommended by most guidelines. Due to moderate ~20-30% rate of understaging on initial TURBT, repeat TURBT is recommended to ensure that MIBC is not missed. However, considering the potential cost implications, patient discomfort, and potential risks of repeat TURBT, there has been renewed interest to reassess the need of repeat TURBT.

SIU 2017: Health-Related Quality of Life, Perceived Social Support, and Depression in Disease-Free Survivors of Surgically Treated Prostate, Kidney and Bladder Cancer: Comparison among Survivors and with the General Population

Lisbon, Portugal ( As cancer care improves, our understanding of the importance of quality of life also improves – while cancer cure is important, it has to be weighed against the potential implications of radical surgery. Certain operations have more QOL implications that others, obviously, but each has its social implications.

SIU 2017: Rationalising Follow Up for Bosniak IIF Cysts: A Multicentre Study

Lisbon, Portugal ( In this study, the authors build upon work they had previously published in 2016. In that study, they demonstrated that in a cohort of 198 patients with Bosniak IIF cysts, only 0.5% progressed into malignant lesions; if they progressed, it was within the first two years of follow-up. They had then recommended that patients with Bosniak IIF cysts could be discharged from follow-up after 2 stable years. In this study, they replicate similar findings in a separate institution.

SIU 2017: Clinical Activity of Abiraterone Acetate in Docetaxel-Naïve and Docetaxel-Pretreated Asian Patients with Metastatic Castration Resistant Prostate Cancer

Lisbon, Portugal ( In this abstract, the authors assess the role of abiraterone acetate, a CYP-17A inhibitor, in chemotherapy-naïve and chemotherapy-treated patients with mCRPC. While this has been established in Level 1 evidence (COU-301 and COU-302 studies), those studies were completed with minimal inclusion of Asian patients. Knowing the disease process is different in this population, the authors assess its efficacy in these disease stages. However, they compare patients treated pre-chemo to those treated after docetaxol, likely in an effort to determine sequencing.

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.